HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner
Presented at: 2019 Society for Immunotherapy of Cancer (SITC)
TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
Presented at: 2019 American Association for Cancer Research (AACR)
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
Carmi Y, et al., Nature (2015)
Systemic immunity is required for effective cancer immunotherapy
Spitzer MH et al., Cell (2017)